Abstract
This Practice Point commentary discusses the findings of a trial that assessed the efficacy of weekly (QW) versus once every 3 weeks (Q3W) paclitaxel or docetaxel after doxorubicin-and-cyclophosphamide-based chemotherapy in patients with node-positive or high-risk node-negative breast cancer. There were several analyses in this trial, the first comparing docetaxel with paclitaxel and the second assessing the impact of schedule of chemotherapy. In an intention to treat analysis, there was no difference in disease-free survival between the two taxanes or between the two dosing schedules. When the four arms of the trial were assessed individually, however, QW paclitaxel was superior to Q3W paclitaxel with respect to disease-free survival (P = 0.006) and overall survival (P = 0.01). Patients on the QW paclitaxel schedule had a greater incidence of grade 2, 3 or 4 peripheral neuropathy than did those on Q3W paclitaxel (27% vs 20%). This study further elucidates the nuances in taxane therapy and supports the concept that attenuating the interval between chemotherapy treatments might lead to improved outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
De Laurentiis M et al. (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26: 44–53
Sparano JA et al. (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358: 1663–1671
Hayes D et al. (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357: 1496–1506
Berry DA et al. (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295: 1658–1667
Citron ML et al. (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439
Kummel S et al. (2006) Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer 94: 1237–1244
Fountzilas G et al. (2008) Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 19: 853–860
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Vahdat, L. Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?. Nat Rev Clin Oncol 5, 570–571 (2008). https://doi.org/10.1038/ncponc1215
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1215